30 likes | 153 Views
Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and Treatment
E N D
Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and Treatment Authors: Anna-Maria Jegg1, Toby M. Ward1, Elizabeth Iorns3, Nicholas Hoe4, JinYao Zhou4, Xiaofei Liu1, Sharat Singh4, Ralf Landgraf2 and Mark D. Pegram1 1Division of Hematology and Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136 2Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136 3Science Exchange, Inc. Palo Alto, CA 94301 4Prometheus Laboratories, San Diego, CA 92121 Corresponding author: Mark D. Pegram; mpegram@stanford.edu
Supplementary Figure 1 A B SK-lapR SKBR3 SK-lapR - + - + 2.6μM lap AZD0530 AZD + lap - DMSO lapatinib 48h 24h 48h 24h 48h 24h 48h 24h 48h p-SRC p-SRCY416 SRC actin p-ERK ERK C SK-lapR PD325901 PD + lap - DMSO lapatinib ERa 48h 24h 48h 24h 48h 24h 48h 24h 48h actin p-ERK1/2T202/T204 actin
Supplementary Figure 2 A B SKBR3 SK-lapR 25 EGFR mRNA 20 15 Relative mRNA expression [fold increase] 10 5 0 SKBR3 SK-lapR EGFR/CEN ratio: 0.99 = no amplification (346/348 in 50 cells) EGFR/CEN ratio: 1.046 = no amplification (383/366) in 50 cells)